Functional Module Connectivity Map (FMCM): A framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Chung, Feng Hsiang ^a   Chiang, Yun Ru ^a   Tseng, Ai Lun ^a   Sung, Yung Chuan ^b   Lu, Jean ^c   Huang, Min Chang ^d   Ma, Nianhan ^a   Lee, Hoong Chien ^a,b,d,e  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^e NATIONAL CENTER FOR THEORETICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

6 AZATHYMINE; 8 AZAGUANINE; ALSTERPAULLONE; ANTINEOPLASTIC AGENT; APIGENIN; CAMPTOTHECIN; CHRYSIN; CYCLOSERINE; DAUNORUBICIN; DOXAZOSIN; ELLIPTICINE; ETACRYNIC ACID; GINKGOLIDE A; GW 8510; IFENPRODIL; IMIPENEM; LUTEOLIN; MEDRYSONE; METICRANE; PHENOXYBENZAMINE; PHTHALYLSULFATHIAZOLE; PYRVINIUM EMBONATE; RNA; SULCONAZOLE; THAPSIGARGIN; THIOGUANOSINE; THIOSTREPTON; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACCURACY; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FUNCTIONAL MODULE CONNECTIVITY MAP; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC PROCEDURES; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; RNA EXTRACTION;

ADENOCARCINOMA; ALGORITHMS; COLORECTAL NEOPLASMS; DRUG REPOSITIONING; EPISTASIS, GENETIC; ETHACRYNIC ACID; GENE REGULATORY NETWORKS; GINKGOLIDES; HUMANS; IMIPENEM; INDOLES; LACTONES; MICROARRAY ANALYSIS; PHENOXYBENZAMINE; SENSITIVITY AND SPECIFICITY; THYMINE;

EID: 84900341330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086299     Document Type: Article

References (65)

1. Sleigh SH, Barton CL (2010) Repurposing Strategies for Therapeutics. Pharmaceutical Medicine 24: 151-159 110.2165/11536770-000000000-000000000.
2. Kamb A, Wee S, Lengauer C (2007) Why is cancer drug discovery so difficult? Nat Rev Drug Discov 6: 115-120. (Pubitemid 46745339)
3. Chong CR, Sullivan DJ, Jr. (2007) New uses for old drugs. Nature 448: 645-646. (Pubitemid 47236844)
4. Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, et al. (2007) Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf 2: 177-185. (Pubitemid 47578123)
5. Hill KD, Wee R (2012) Psychotropic Drug-Induced Falls in Older People A Review of Interventions Aimed at Reducing the Problem. Drugs & Aging 29: 15-30.
6. Goldkind L, Laine L (2006) A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 15: 213-220.
7. Imming P, Sinning C, Meyer A (2006) Opinion - Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery 5: 821-834. (Pubitemid 44480536)
8. Merino A, Bronowska AK, Jackson DB, Cahill DJ (2010) Drug profiling: knowing where it hits. Drug Discov Today 15: 749-756.
9. Rettig RA (2006) The war on cancer: An anatomy of failure, a blueprint for the future. Health Affairs 25: 1446-1447.
10. Kreeger PK, Lauffenburger DA (2010) Cancer systems biology: a network modeling perspective. Carcinogenesis 31: 2-8.
11. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
12. Schadt EE, Friend SH, Shaywitz DA (2009) A network view of disease and compound screening. Nat Rev Drug Discov 8: 286-295.
13. Berger SI, Iyengar R (2009) Network analyses in systems pharmacology. Bioinformatics 25: 2466-2472.
14. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
15. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J (2006) Cancer: a Systems Biology disease. Biosystems 83: 81-90. (Pubitemid 43199809)
16. Oprea TI, Mestres J (2012) Drug repurposing: far beyond new targets for old drugs. AAPS J 14: 759-763.
17. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935. (Pubitemid 44497995)
18. Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, et al. (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A 105: 19432-19437.
19. Huang L, Zhao S, Frasor JM, Dai Y (2011) An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One 6: e22274.
20. Wang G, Ye Y, Yang X, Liao H, Zhao C, et al. (2011) Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One 6: e14573.
21. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, et al. (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3: 96ra76.
22. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, et al. (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3: 96ra77.
23. Shigemizu D, Hu ZJ, Hung JH, Huang CL, Wang YJ, et al. (2012) Using Functional Signatures to Identify Repositioned Drugs for Breast, Myelogenous Leukemia and Prostate Cancer. Plos Computational Biology 8.
24. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, et al. (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2: ra31.
25. Kumar N, Afeyan R, Kim HD, Lauffenburger DA (2008) Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol 73: 1668-1678. (Pubitemid 351724356)
26. Chung FH, Lee HH, Lee HC (2013) ToP: A Trend-of-Disease-Progression Procedure Works Well for Identifying Cancer Genes from Multi-State Cohort Gene Expression Data for Human Colorectal Cancer. PLoS One 8: e65683.
27. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, et al. (2007) Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5: 1263-1275.
28. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37: D767-772.
29. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics 25: 25-29. (Pubitemid 30257031)
30. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-1136.
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. (Pubitemid 41528093)
32. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121. (Pubitemid 32397092)
33. Alexa A, Rahnenfuhrer J, Lengauer T (2006) Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 22: 1600-1607. (Pubitemid 43985293)
34. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
35. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
36. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
37. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047. (Pubitemid 30162806)
38. Rogers TB, Inesi G, Wade R, Lederer WJ (1995) Use of thapsigargin to study Ca2+ homeostasis in cardiac cells. Bioscience Reports 15: 341-349. (Pubitemid 26050853)
39. Frei E, 3rd, Holland JF, Schneiderman MA, Pinkel D, Selkirk G, et al. (1958) A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 13: 1126-1148.
40. Vaidyanathan S, Mansour P, Soni BM, Hughes PL, Singh G (2006) Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy. Spinal Cord 44: 188-191. (Pubitemid 43348381)
41. Brambilla G, Martelli A (2006) Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat Res 612: 115-149. (Pubitemid 43224248)
42. Pereira M, Millot JM, Sebille S, Manfait M (2002) Inhibitory effects of extracellular Mg2+ on intracellular Ca2+ dynamic changes and thapsigargin-induced apoptosis in human cancer MCF7 cells. Mol Cell Biochem 229: 163-171. (Pubitemid 34187689)
43. Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT (2000) Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 43: 303-317. (Pubitemid 30367966)
44. Lin XS, Denmeade SR, Cisek L, Isaacs JT (1997) Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 33: 201-207. (Pubitemid 27509421)
45. Hakii H, Fujiki H, Suganuma M, Nakayasu M, Tahira T, et al. (1986) Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanoylphorbol-13- acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis. J Cancer Res Clin Oncol 111: 177-181. (Pubitemid 16093075)
46. Harmon CS, Ducote J, Xiong Y (1996) Thapsigargin induces rapid, transient growth inhibition and c-fos expression followed by sustained growth stimulation in mouse keratinocyte cultures. J Invest Dermatol 107: 188-194. (Pubitemid 26254832)
47. Lee DI, Sumbilla C, Lee M, Natesavelalar C, Klein MG, et al. (2007) Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells. Arch Biochem Biophys 464: 19-27. (Pubitemid 47088360)
48. Kent LL, Hull-Campbell NE, Lau T, Wu JC, Thompson SA, et al. (1999) Characterization of novel inhibitors of cyclin-dependent kinases. Biochem Biophys Res Commun 260: 768-774. (Pubitemid 29371125)
49. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M, et al. (2003) Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 94: 886-893. (Pubitemid 37406971)
50. Seyfried J, Soldner F, Schulz JB, Klockgether T, Kovar KA, et al. (1999) Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neurosci Lett 264: 1-4. (Pubitemid 29195934)
51. Lu D, Liu JX, Endo T, Zhou H, Yao S, et al. (2009) Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 4: e8294.
52. Rhodes T, Twentyman PR (1992) A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines. Br J Cancer 65: 684-690.
53. Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, et al. (1994) Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther 270: 1186-1191. (Pubitemid 24315238)
54. Tew KD, Bomber AM, Hoffman SJ (1988) Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625.
55. Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, et al. (2010) Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res 24: 445-450.
56. Ahlemeyer B, Krieglstein J (2003) Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry 36 Suppl 1: S8-14.
57. Shi C, Liu J, Wu F, Yew DT (2010) Ginkgo biloba extract in Alzheimer's disease: From action mechanisms to medical practice. Int J Mol Sci 11: 107-123.
58. Xia SH, Fang DC (2007) Pharmacological action and mechanisms of ginkgolide B. Chin Med J (Engl) 120: 922-928.
59. Aponte MM, Kwong J, Mok SC, Berkowitz RS, Cramer DW, et al. (2006) Gingkolide may prevent ovarian cancer through the platelet activating factor receptor (PAFR) pathway. AACR Meeting Abstracts 2006: A106-.
60. Jiang W, Qiu W, Wang Y, Cong Q, Edwards D, et al. (2011) Ginkgo may prevent genetic-associated ovarian cancer risk: multiple biomarkers and anticancer pathways induced by ginkgolide B in BRCA1-mutant ovarian epithelial cells. Eur J Cancer Prev 20: 508-517.
61. Jiang W, Cong Q, Wang Y, Ye B, Xu C (2012) Ginkgo May Sensitize Ovarian Cancer Cells to Cisplatin: Antiproliferative and Apoptosis-Inducing Effects of Ginkgolide B on Ovarian Cancer Cells. Integr Cancer Ther.
62. DeFeudis FV, Papadopoulos V, Drieu K (2003) Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam Clin Pharmacol 17: 405-417. (Pubitemid 36920641)
63. Prusoff WH, Holmes WL, Welch AD (1954) Biological investigations of 6-azathymine, a thymine analog. Cancer Res 14: 570-574.
64. Ellison RR, Tan CT, Murphy ML, Krakoff IH (1960) [Clinical investigations of 6-azathymine: a thymine analog]. Cancer Res 20: 435-442.
65. Khamas A, Ishikawa T, Shimokawa K, Mogushi K, Iida S, et al. (2012) Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2′-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteomics 9: 67-75.